In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or maybe the contributors are unable to tolerate the study drugs. Total, our present work highlights the potential utilization of ARV-825 in combination https://motherr998epz1.wikigdia.com/user